RSV in 2023: Protecting Against the Resurgence

Introduction

As we move further into 2023, the medical community is once again facing a concerning resurgence of respiratory syncytial virus (RSV). The U.S. Centers for Disease Control and Prevention (CDC) has issued warnings regarding elevated RSV cases, primarily in the Southeastern United States. This recent increase in RSV infections serves as a potential harbinger of a nationwide outbreak in the coming months. In light of this concerning development, the CDC is urging medical professionals to prepare for RSV by utilizing newly approved treatments and prevention options. In this article, we’ll explore the significance of this RSV resurgence, the available preventive measures, and how using personal protective equipment (PPE) and frequent testing are crucial strategies to combat RSV.

The RSV Resurgence: A Cause for Concern

The CDC’s warning about the increase in RSV cases in the Southeastern United States is not to be taken lightly. Historically, regional surges in RSV cases have signaled the beginning of a nationwide outbreak, with RSV activity spreading northward and westward over the subsequent two to three months. RSV typically follows a seasonal pattern, with the season starting in the fall and peaking in the winter. However, pandemic-related prevention measures have disrupted this pattern. Last year, RSV activity began in the summer, peaked in the fall, and declined by winter.

The Impact of RSV

RSV poses a significant threat, especially to vulnerable populations. Infants, young children, and older adults, particularly those with underlying medical conditions, are at increased risk of severe disease from RSV infection. Each year, RSV leads to approximately 80,000 hospitalizations and 300 deaths in children under the age of 5, as well as 160,000 hospitalizations and 10,000 deaths in adults aged 65 and older.

Preventing RSV: A Multifaceted Approach

The CDC emphasizes using newly approved treatments and prevention methods to protect public health. Here are some important steps to keep in mind:

1. Monoclonal Antibodies for Infants: Nirsevimab, also known as Beyfortus, is a monoclonal antibody designed to protect infants against RSV. It was approved in July and offers significant protection. The CDC recommends that all infants under 8 months should receive a single dose of this treatment. Additionally, infants and children ages 8 months to 19 months who are at an increased risk for severe RSV disease should also get one dose before or during their second season. Nirsevimab is expected to become available in early October.

2. Vaccination for Adults: For adults aged 60 and older, there are two RSV vaccines available: Pfizer’s Abrysvo and GSK’s Arexvy. These vaccines offer protection against severe RSV cases. The CDC recommends that individuals in this age group consult their doctors about the benefits and risks of vaccination. Additionally, theFDA has approved Abrysvo for use in pregnant individuals to protect infants from RSV.

The Role of PPE and Frequent Testing

In addition to these treatments and vaccines, the use of personal protective equipment (PPE) and frequent testing is crucial in controlling the spread of RSV. Infected individuals primarily transmit RSV through respiratory droplets when they cough or sneeze or through contact with contaminated surfaces. To minimize the risk of infection, healthcare professionals, caregivers, and individuals should wear appropriate PPE, such as masks, gloves, and gowns, when in close contact with RSV patients.

Moreover, regular testing for RSV is necessary to quickly identify and isolate infected individuals. CrowdHealth, your trusted medical supply distribution company, offers a range of PPE and testing supplies to ensure the safety of health professionals and patients alike.

Conclusion

As we navigate RSV in 2023, it’s key that we  take proactive measures. Utilizing the newly approved treatments and vaccines is a crucial step in this battle against RSV. Additionally, the use of PPE and frequent testing is vital to reduce the risk of transmission. CrowdHealth is here to support your efforts in combating RSV by providing PPE and testing supplies. Together, we can work towards a safer and healthier future.

Learn more about CrowdHealth’s RSV solutions here

Read more about RSV here:

• https://www.washingtonpost.com/health/2023/09/06/cdc-rsv-vaccine-guidelines/
• https://www.latimes.com/california/story/2023-09-06/rsv-season-may-have-already-begun-cdc-warns

‍